In this webinar, hosted by DDW and sponsored by BPS BioScience and ACROBiosystems, you will learn about the biggest opportunities for the future of cancer immunotherapy.
You will hear from immunologist Dr Frédéric Triebel, CSO and CMO of Immutep, two experts from DeciBio: Dr Carl Schoellhammer, Principal, and Dr Joe Daccache, Senior Life Science Expert, Veronique Baron, Scientific Applications Manager, Marketing at BPS Bioscience, and Dr Hengshuo Liu, Technical Sales Specialist at ACROBiosystems.
Cell therapies are an important class of therapy in immuno-oncology. They have the power to treat in a differentiated manner the disease but face their own unique challenges in development and production. Dr Schoellhammer and Dr Daccache review key development points for the field and hurdles that are being addressed to develop better tools for production and qualification of these therapies.
Veronique Baron from BPS Bioscience discusses the tools required to research and develop new oncology therapies, such as proteins, antibodies, cell lines, assay kits and viral tools. She will share information on new research solutions, including a new line of CAR-T cells, cell-based and biochemical assays, and the variety of ways that BPS Bioscience can enable the fight against diseases such as cancer.
In another presentation, Dr. Hengshuo Liu from ACROBiosystems will examine the areas where proteins and innovation are advancing biomedicine.
What you will learn:
- What is the next phase of cancer immunotherapy and what should researchers be focusing on to move to this next step?
- Where are the long-term opportunities and what challenges are there?
An audience Q&A session with the presenter follows the webinar presentation.
